T CELL TARGETING FOR GVHD

$435,801R37FY2007HLNIH

University Of Minnesota, Minneapolis MN

Investigators

Linked publications & trials

Paper 34424962 Paper 31578305 Paper 31343575 Paper 31182480 Paper 31170216 Paper 30906290 Paper 30886050 Paper 30885956 Paper 30877143 Paper 30694220 Paper 30664665 Paper 30625388 Paper 30574153 Paper 30518925 Paper 30385732 Paper 30291167 Paper 30106752 Paper 30102255 Paper 29988091 Paper 29973721 Paper 29941459 Paper 29784636 Paper 29728511 Paper 29728401 Paper 29720426 Paper 29565806 Paper 29463561 Paper 29459719 Paper 29445371 Paper 29343444 Paper 28931653 Paper 28652577 Paper 28159900 Paper 27294527 Paper 25814530 Paper 25359003 Paper 25271622 Paper 24030385 Paper 23684987 Paper 22408260 Paper 22300641 Paper 22177005 Paper 21881045 Paper 21835147 Paper 21820917 Paper 21813777 Paper 21593401 Paper 21564534 Paper 21070606 Paper 20819927 Paper 20807889 Paper 20442366 Paper 19843883 Paper 19828695 Paper 19464988 Paper 19458354 Paper 19260829 Paper 19050298 Paper 18957685 Paper 18832696 Paper 18684977 Paper 18645038 Paper 18614760 Paper 18292520 Paper 18285547 Paper 18077788 Paper 17924994 Paper 17911605 Paper 17606761 Paper 17448912 Paper 17182565 Paper 17129175 Paper 16861937 Paper 16728286 Paper 16567639 Paper 16458015 Paper 16160014 Paper 16147539 Paper 16020508 Paper 16002422 Paper 15701715 Paper 15618467 Paper 15522961 Paper 15374887 Paper 15322151 Paper 15292057 Paper 15031211 Paper 14688306 Paper 14627918 Paper 12874215 Paper 12750162 Paper 12609834 Paper 12521997 Paper 12463476 Paper 12384443 Paper 12108917 Paper 12036894 Paper 11986199 Paper 11854328 Paper 11698438

Abstract

DESCRIPTION: (Applicant's Abstract) Ex vivo T cell depletion (TCD), is[unreadable] highly effective for lethal graft-vs.-host disease (GVHD) prevention.[unreadable] However, T cell removal may compromise beneficial donor T cell responses.[unreadable] Pharmacological agents are incompletely efficacious in preventing GVHD and[unreadable] have significant side-effects. Rather than broadly eliminate T cells or T[unreadable] cell subsets, the applicants propose to functionally alter ex vivo the small[unreadable] proportion of donor T cells with anti-host alloreactive potential. In aim[unreadable] 1, two types of ex vivo approaches are proposed to inhibit CD4+ T cell[unreadable] mediated GVHD lethality. The first involves physically blocking the[unreadable] interaction of cell surface determinants on donor T cells with those on host[unreadable] antigen-presenting cells. The CD40L, CD40 and CD28/B7 pathways will be[unreadable] targeted. The second involves targeting intracellular signalling pathways[unreadable] (PI3K, Jak3) required for optimal T cell responses. A series of studies[unreadable] using wild-type and various knockout (ko) mice are proposed in aim 1 which[unreadable] will investigate the mechanism(s) responsible for inducing alloantigen[unreadable] hyporesponsiveness. In aim 2A, successful tolerization approaches will be[unreadable] applied to CD4+ and CD8+ T cell containing donor inoculum. In aim 2B, T[unreadable] cell receptor (TCR) transgenic systems will be used to track CD4+ or CD8+[unreadable] TCR clonotypes that are capable of specifically responding to alloantigen or[unreadable] nominal antigen. These studies will provide important information regarding[unreadable] the mechanism(s) responsible for tolerance induction and the specificity of[unreadable] these approaches as measured by bystander effects on nominal antigen[unreadable] responses. In aim 2C, the effects of tolerance induction on[unreadable] graft-versus-leukemia (GVL) will be analyzed using a delayed lymphocyte[unreadable] infusion model system. This application will provide new strategies for ex[unreadable] vivo GVHD prevention and will provide important data on the mechanism(s) and[unreadable] specificity of such approaches in clinically relevant model systems.[unreadable]

View original record on NIH RePORTER →